304 related articles for article (PubMed ID: 23243198)
1. Prognostic impact of (18)FDG-PET-CT findings in clinical stage III and IIB breast cancer.
Groheux D; Hindié E; Delord M; Giacchetti S; Hamy AS; de Bazelaire C; de Roquancourt A; Vercellino L; Toubert ME; Merlet P; Espié M
J Natl Cancer Inst; 2012 Dec; 104(24):1879-87. PubMed ID: 23243198
[TBL] [Abstract][Full Text] [Related]
2. Clinical significance of FDG-PET/CT at the postoperative surveillance in the breast cancer patients.
Jung NY; Yoo IR; Kang BJ; Kim SH; Chae BJ; Seo YY
Breast Cancer; 2016 Jan; 23(1):141-148. PubMed ID: 24872087
[TBL] [Abstract][Full Text] [Related]
3. Comparison of 18F-FDG PET/CT for Systemic Staging of Newly Diagnosed Invasive Lobular Carcinoma Versus Invasive Ductal Carcinoma.
Hogan MP; Goldman DA; Dashevsky B; Riedl CC; Gönen M; Osborne JR; Jochelson M; Hudis C; Morrow M; Ulaner GA
J Nucl Med; 2015 Nov; 56(11):1674-80. PubMed ID: 26294295
[TBL] [Abstract][Full Text] [Related]
4. (18)F-FDG-PET/CT for systemic staging of newly diagnosed triple-negative breast cancer.
Ulaner GA; Castillo R; Goldman DA; Wills J; Riedl CC; Pinker-Domenig K; Jochelson MS; Gönen M
Eur J Nucl Med Mol Imaging; 2016 Oct; 43(11):1937-44. PubMed ID: 27129866
[TBL] [Abstract][Full Text] [Related]
5. ¹⁸F-FDG PET/CT provides powerful prognostic stratification in the primary staging of large breast cancer when compared with conventional explorations.
Cochet A; Dygai-Cochet I; Riedinger JM; Humbert O; Berriolo-Riedinger A; Toubeau M; Guiu S; Coutant C; Coudert B; Fumoleau P; Brunotte F
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):428-37. PubMed ID: 24196916
[TBL] [Abstract][Full Text] [Related]
6. The yield of 18F-FDG PET/CT in patients with clinical stage IIA, IIB, or IIIA breast cancer: a prospective study.
Groheux D; Giacchetti S; Espié M; Vercellino L; Hamy AS; Delord M; Berenger N; Toubert ME; Misset JL; Hindié E
J Nucl Med; 2011 Oct; 52(10):1526-34. PubMed ID: 21880576
[TBL] [Abstract][Full Text] [Related]
7. Retrospective analysis of 18F-FDG PET/CT for staging asymptomatic breast cancer patients younger than 40 years.
Riedl CC; Slobod E; Jochelson M; Morrow M; Goldman DA; Gonen M; Weber WA; Ulaner GA
J Nucl Med; 2014 Oct; 55(10):1578-83. PubMed ID: 25214641
[TBL] [Abstract][Full Text] [Related]
8. 18F-FDG PET/CT has a high impact on patient management and provides powerful prognostic stratification in the primary staging of esophageal cancer: a prospective study with mature survival data.
Barber TW; Duong CP; Leong T; Bressel M; Drummond EG; Hicks RJ
J Nucl Med; 2012 Jun; 53(6):864-71. PubMed ID: 22582047
[TBL] [Abstract][Full Text] [Related]
9. 18F-FDG PET/CT in staging patients with locally advanced or inflammatory breast cancer: comparison to conventional staging.
Groheux D; Giacchetti S; Delord M; Hindié E; Vercellino L; Cuvier C; Toubert ME; Merlet P; Hennequin C; Espié M
J Nucl Med; 2013 Jan; 54(1):5-11. PubMed ID: 23213197
[TBL] [Abstract][Full Text] [Related]
10.
Ulaner GA; Castillo R; Wills J; Gönen M; Goldman DA
Eur J Nucl Med Mol Imaging; 2017 Aug; 44(9):1420-1427. PubMed ID: 28456837
[TBL] [Abstract][Full Text] [Related]
11. Detection of internal mammary lymph node metastasis with (18)F-fluorodeoxyglucose positron emission tomography/computed tomography in patients with stage III breast cancer.
Seo MJ; Lee JJ; Kim HO; Chae SY; Park SH; Ryu JS; Ahn SH; Lee JW; Son BH; Gong GY; Moon DH
Eur J Nucl Med Mol Imaging; 2014 Mar; 41(3):438-45. PubMed ID: 24196918
[TBL] [Abstract][Full Text] [Related]
12. Clinicopathological and prognostic relevance of uptake level using 18F-fluorodeoxyglucose positron emission tomography/computed tomography fusion imaging (18F-FDG PET/CT) in primary breast cancer.
Ueda S; Tsuda H; Asakawa H; Shigekawa T; Fukatsu K; Kondo N; Yamamoto M; Hama Y; Tamura K; Ishida J; Abe Y; Mochizuki H
Jpn J Clin Oncol; 2008 Apr; 38(4):250-8. PubMed ID: 18407934
[TBL] [Abstract][Full Text] [Related]
13. The role of (18)F-FDG PET/CT in the diagnosis of breast cancer and lymph nodes metastases and micrometastases may be limited.
Zhang X; Wu F; Han P
Hell J Nucl Med; 2014; 17(3):177-83. PubMed ID: 25526754
[TBL] [Abstract][Full Text] [Related]
14. Prognostic impact of 18F-FDG PET/CT staging and of pathological response to neoadjuvant chemotherapy in triple-negative breast cancer.
Groheux D; Giacchetti S; Delord M; de Roquancourt A; Merlet P; Hamy AS; Espié M; Hindié E
Eur J Nucl Med Mol Imaging; 2015 Mar; 42(3):377-85. PubMed ID: 25432784
[TBL] [Abstract][Full Text] [Related]
15. Preoperative 18F-FDG PET/CT predicts disease-free survival in patients with primary invasive ductal breast cancer.
Jo JE; Kim JY; Lee SH; Kim S; Kang T
Acta Radiol; 2015 Dec; 56(12):1463-70. PubMed ID: 25406431
[TBL] [Abstract][Full Text] [Related]
16. Accuracy of 18F-FDG PET/CT for primary tumor visualization and staging in T1 breast cancer.
Koolen BB; van der Leij F; Vogel WV; Rutgers EJ; Vrancken Peeters MJ; Elkhuizen PH; Valdés Olmos RA
Acta Oncol; 2014 Jan; 53(1):50-7. PubMed ID: 23672678
[TBL] [Abstract][Full Text] [Related]
17. Risk stratification in patients with advanced-stage breast cancer by pretreatment [(18) F]FDG PET/CT.
Chen S; Ibrahim NK; Yan Y; Wong ST; Wang H; Wong FC
Cancer; 2015 Nov; 121(22):3965-74. PubMed ID: 26249241
[TBL] [Abstract][Full Text] [Related]
18. Impact of Pretreatment Combined (18)F-Fluorodeoxyglucose Positron Emission Tomography/Computed Tomography Staging on Radiation Therapy Treatment Decisions in Locally Advanced Breast Cancer.
Ng SP; David S; Alamgeer M; Ganju V
Int J Radiat Oncol Biol Phys; 2015 Sep; 93(1):111-7. PubMed ID: 26279029
[TBL] [Abstract][Full Text] [Related]
19. Diagnostic performance of fluorodeoxyglucose-positron emission tomography/computed tomography combined with ultrasonography-guided fine needle aspiration cytology for identifying axillary lymph node status in patients with breast cancer.
Machida Y; Kubota K; Katayama T; Toriihara A; Shibuya H
Eur J Surg Oncol; 2013 Jan; 39(1):26-30. PubMed ID: 23122913
[TBL] [Abstract][Full Text] [Related]
20. Clinical utility of F-18 FDG PET/CT in recurrent breast carcinoma.
Manohar K; Mittal BR; Senthil R; Kashyap R; Bhattacharya A; Singh G
Nucl Med Commun; 2012 Jun; 33(6):591-6. PubMed ID: 22334135
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
